223488-57-1

Basic information

• Product Name: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid
• Synonyms: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid;CP-533536;Evatanepag
• CAS NO: 223488-57-1
• Molecular Formula: C₂₅H₂₈N₂O₅S
• Molecular Weight: 468.56
• Mol File: 223488-57-1.mol

Chemical Properties

• Boiling Point: 660.15 °C at 760 mmHg
• Flash Point: 353.046 °C
• Appearance: /
• Density: 1.262 g/cm³
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid(223488-57-1)
• EPA Substance Registry System: 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid(223488-57-1)

Safety Data

• Hazardous Substances Data: 223488-57-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid is used as a pharmaceutical agent for the development of drugs targeting specific receptors or pathways. Its unique structure allows for the modulation of biological processes, making it a promising candidate for the treatment of various diseases.
Used in Drug Discovery and Development:
In the field of drug discovery and development, 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid serves as a lead compound for the design and synthesis of new therapeutic agents. Its chemical properties and structural features can be further optimized to enhance its efficacy, selectivity, and safety profile.
Used in Research Applications:
2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid is also utilized in research settings to study the mechanisms of action and potential interactions with biological targets. This knowledge can contribute to a better understanding of disease pathways and the development of more effective treatments.
Used in Bone Growth Induction:
As an EP2 receptor selective prostaglandin E2 agonist, 2-[3-[N-(4-tert-Butylbenzyl)-N-(pyridin-3-ylsulfonyl)aminomethyl]phenoxy]acetic acid, also known as Evatanepag, is used for inducing bone growth. This application is particularly relevant in the treatment of conditions that involve bone loss or impaired bone formation, such as osteoporosis or fractures.

Upstream product

• 223492-52-2 {3-[(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy acetic acid tert-butyl ester 

Downstream Products

• 1126076-53-6 (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt monohydrate 
• 223490-49-1 CP-533,536 

Relevant articles and documents

POLYMORPHS OF PROSTAGLANDIN AGONISTS AND METHODS FOR MAKING THE SAME

The present invention relates to polymorphic crystalline forms or a non- crystalline form or amorphous of the compound (3-(((4-tert-butyl-benzyl)-(pyridine- 3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof together with pro

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an EP2 or EP4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compositions and methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 and an EP2 or EP4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof.

Methods of treatment using an EP2 selective receptor agonist

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.

Pharmaceutical compositions and methods for administering EP2 receptor selective agonists

This invention is directed to pharmaceutical compositions and methods comprising prostglandin agonists, specifically EP2 receptor selective agonists, which are useful to enhance bone repair and healing and restore or augment bone mass in vertebrates, particularly mammals. The EP2 receptor selective agonists of the present invention are effective in the treatment of conditions such as those in which the patient has delayed or non-union fracture, bone defect, spinal fusion, bone in-growth, cranial facial reconstruction or bone sites at risk for fracture.

Controlled release polymeric compositions of bone growth promoting compounds

The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of a bone growth promoting compound to certain tissues.

Treatment of osteoporsis with EP2/EP4 receptor selective agonists

This invention is directed to methods and pharmaceutical compositions comprising prostaglandin agonists which are userful to prevent bone loss, restore or augment bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass, such as osteoporosis, and/or bone defects in vertebrates, and particularly mammals, including humans. This invention specifically relates to methods and pharmaceutical compositions comprising combinations of EP2 receptor selective agonists and EP4 receptor selective agonists and to methods and pharmaceutical compositions comprising agents which are agonists for both the EP2 receptor and the EP4 receptor.

Use of prostaglandin agonists to treat erectile dysfunction or impotence

The present invention relates to methods of treating impotence or erectile dysfunction which comprise administering to a patient in need of such treatment an impotence or erectile dysfunction treating amount of a prostaglandin receptor agonist.